Our Proprietary Products business comprises of New Chemical Entities (NCEs), Biosimilars and Differentiated Formulations.
In NCE, we are engaged in the discovery, development, and commercialization of novel small molecule agents to address significant clinical unmet needs. Our therapeutic areas of focus are bacterial infections, metabolic disorders, and pain/ inflammation..
Our emerging Differentiated Formulations portfolio consists of developing novel formulations of currently marketed drugs or combinations thereof to enhance patient comfort. Our most advanced Differentiated Formulations efforts are in dermatology.
Promius Pharma, our wholly owned subsidiary, headquartered in New Jersey, US, develops and markets differentiated formulations for important dermatology indications. Our portfolio includes in-licensed and co-developed dermatological products and an internal pipeline of products under development that will provide better answers to the skin care needs of today and tomorrow.
Our Biologics business has dedicated development and manufacturing suites for both E. coli & mammalian cell culture, conforming to the highest development standards of cGMP, GLP and other applicable bio-safety levels. seamlessly by a competent project management framework.